Summary
Other Scenarios:
- SNY - GSK
- SNY - JNJ
- GSK - RHHBY
- JNJ - RHHBY
| Buyer: | Sanofi-Aventis SA (ADR) (SNY) | Last Price: | 37.33 | Market Cap.: | 48.97B |
|---|---|---|---|---|---|
| Target: | Roche Holding Ltd. (ADR) (RHHBY) | Last Price: | 41.12 | Market Cap.: | 35.47B |
Lines of Business Summary:
- Sanofi-Aventis SA (ADR) (SNY) competes in 2 industries and 268 product/service groups
- Roche Holding Ltd. (ADR) (RHHBY) competes in 1 industry and 218 product/service groups
- A combined entity will have 4% Product/Service Group overlap
- Sanofi-Aventis SA (ADR) (SNY) has 7 and Roche Holding Ltd. (ADR) (RHHBY) has 16 suppliers that rely on a material % of their business. They share 1 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Consumer |
|
898 | |
Consumer Products and Services |
|
353 | |
|
Healthcare |
|
|
777 |
|
Biopharmaceuticals |
|
|
344 |
|
Healthcare Services |
|
|
134 |
|
Medical Devices |
|
|
193 |
|
Nutritional Health |
|
30 | |
|
Outsourced Biomedical Services |
|
|
40 |
|
Scientific Products |
|
25 | |
|
Veterinary Products and Services |
|
9 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 326)
|
Target (Total: 287)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 60)
|
Target (Total: 65)
|
Buyer (Total: 19)
|
Target (Total: 36)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 101,575 | 80,653 |
| Revenue Per Employee | 473,388.5 | 677,814.8 |
| Total Revenue | 12,153.6 | 23,863.1 |
| Total Expenses | 10,138.9 | 18,639.5 |
Other Revenue
|
612.7 | 0.0 |
|
Cost of Revenue
|
3,507.2 | 6,711.6 |
|
SG&A Expense
|
2,867.8 | 7,257.1 |
|
Research & Development
|
1,632.0 | 5,804.6 |
|
Other Operating Expense
|
811.5 | -852.7 |
|
Operating Income
|
2,014.7 | 5,223.6 |
|
Unusual Income
|
228.5 | -281.1 |
|
LT Debt to Capital
|
n/a | 74.63 |
|
Fwd P/E
|
7.54 | 9.86 |
|
Fwd P/Rev
|
1.01 | 0.71 |
| Book Value | n/a | 9,894.5 |
|
Curr Portion of LTD/Cap Lease
|
n/a | 2,299.9 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Healthcare > Biopharmaceuticals
Business Description
Buyer
Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. The Company?s business includes two main activities: pharmaceuticals and human vaccines through sanofi pasteur. The Company is also present in animal health products through Merial Limited (Merial). In its pharmaceutical activity, the Company specializes in six therapeutic areas: diabetes, oncology, thrombosis and cardiovascular, central nervous system (CNS), and internal medicine. The global portfolio of sanofi-aventis also consists of a range of other pharmaceutical products in Consumer Health Care (CHC) and other prescription drugs, including generics. It offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines and travel and endemic vaccines. In October 2010, Siegfried Holding AG sold its PulmoJet Inhalation Project to the Company.
Target
Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company?s Diagnostics Division includes five sub-divisions: Roche Applied Science, Roche Diabetes Care, Roche Molecular Diagnostics, Roche Tissue Diagnosis and Roche Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
72.06 | 71.99 |
|
Operating Margin %
|
16.3 | 28.07 |
|
Quick Ratio
|
n/a | 1.36 |
|
Current Ratio
|
n/a | 1.84 |
|
Coverage Ratio
|
-0.09 | 0 |
| Total Assets | n/a | 63,761.8 |
| Return on Equity % | n/a | 88.52 |
| Return on Assets % | n/a | 13.74 |
|
Cash+ ST Inv. Per Share
|
0 | 3.33 |
| Total Debt | 0.0 | 31,408.6 |
| Total Debt to Equity % | n/a | 317.44 |
| Total Debt to Tangible Equity % | n/a | n/a |
|
Debt to Asset %
|
n/a | 49.26 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Consumer |
|
|
Consumer Products and Services |
|
|
|
Personal Care and Cleaning Products
Companies engaged in the manufacturing of personal care products, such as cosmetics, fragrances, skin lotion, sanitary/personal care paper (tissues), shampoo and other toiletries; and household cleaning products, such as window/surface cleaner, and table polish.
|
|
|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes therapeutics that treat and manage weight disorders.
|
|
|
|
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
|
|
|
|
Healthcare Services |
|
|
|
Healthcare Distributors
The Distributors Subsector is comprised of companies that distribute a wide variety of healthcare products, equipment and supplies to healthcare service providers and institutions.
|
|
|
|
Patient Care
The Patient Care Subsector is comprised of companies that provide services to patients for the diagnosis, treatment, and/or prevention of diseases and injuries.
|
|
|
|
Medical Devices |
|
|
|
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
|
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
|
Ear/Nose/Throat (ENT)
The Ear/Nose/Throat Subsector includes medical devices that diagnose and treat conditions affecting these anatomical regions.
|
|
|
|
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
|
|
|
|
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
|
|
|
|
Plastic/Reconstructive Surgery
The Plastic/Reconstructive Surgery Subsector includes medical devices that treat and modify a patient's external appearance.
|
|
|
|
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
|
|
|
|
Nutritional Health |
|
|
|
Complementary and Alternative Medicine (CAM)
The Complementary and Alternative Medicine Subsector includes non-conventional drugs and therapies that are often derived from natural sources to support general health and/or treat diseases. Most of these drugs and therapies have not been formally tested in human clinical trials for their efficacies and safety. Examples include acupuncture, homeopathy, aromatherapy, naturopathy, traditional Chinese medicine (TCM), etc.
|
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Analytical Services
The Analytical Services Subsector includes outsourced services that utilize analytical instruments to analyze biological and chemical samples.
Target Products:
|
|
|
|
Bioanalytical Services
The Bioanalytical Services Subsector includes outsourced services that utilize bioanalytical instruments to analyze biological samples.
|
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
|
|
|
|
Drug Discovery Services
The Drug Discovery Services Subsector includes companies that provide biopharmaceutical companies with novel biological targets and drug leads.
|
|
|
|
Scientific Products |
|
|
|
Analytical Instruments
The Analytical Instruments Subsector includes scientific products that determine the quantitative and qualitative nature of chemical and biochemical samples.
|
|
|
|
Bioanalytical Instruments
The Bioanalytical Subsector includes scientific products, devices, apparatuses, and consumables used to determine the quantitative and qualitative nature of a biological samples.
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Consumer |
|
|
|
Consumer Products and Services |
|
|
Personal Care and Cleaning Products |
|
|
|
Hair Care
Companies engaged in the manufacturing of hair care products, such as shampoo, conditioner, hair dye, hair spray, styling gel, and mousse. Also includes hair accessories, such as pins, clips, and curlers.
Buyer Products:
|
|
|
|
Oral Care
Oral Care products, including Toothpaste, Mouthwash, and denture adhesive.
Buyer Products:
|
|
|
|
Skin Care
Companies engaged in the manufacturing of skin care products, such as suntan lotion, skin lotion, sanitizer, shaving cream, and moisturizer. Also includes manufacturers of non-electrical shaving equipment.
Buyer Products:
|
|
|
|
Soap/Body Wash
Soap, Body Wash, and Shower Gel.
Buyer Products:
|
|
|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
Upper Respiratory |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat allergic reactions by specifically binding and inhibiting inflammatory substances.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.
Buyer Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Acute Coronary Syndrome (ACS) |
|
|
|
Anticoagulating Agents |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat angina by inhibiting the action of adenosine diphosphate (ADP), which in turn inhibits the aggregation of platelets.
Buyer Products:
|
|
|
|
Factor Xa Inhibitors
Therapeutics that treat acute coronary syndrome by due to platelets and cell matter by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Angina |
|
|
|
Anticoagulating Agents |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Arrhythmia |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
Target Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Anticoagulating Agents |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the action of adenosine diphosphate (ADP), which in turn inhibits the aggregation of platelets.
Buyer Products:
|
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Thrombolytic Agents
Therapeutics that treat the ineffective pumping of the heart by dissolving blood clots in blood vessels.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Atherosclerosis |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat the narrowing or hardening of the arteries by inhibiting the action of adenosine diphosphate (ADP), which in turn inhibits the aggregation of platelets.
Buyer Products:
|
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Hypertension |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
Target Products:
|
|
|
|
Hypovolemia |
|
|
|
Plasma Volumizers |
|
|
|
Albumin-Based
Therapeutics based on plasma proteins that treat a decrease in circulating fluid (plasma) in the body by increasing plasma volume.
Buyer Products:
|
|
|
|
Peripheral Vascular Disease |
|
|
|
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.
Buyer Products:
|
|
|
|
Fibroblast Growth Factor-1 (FGF-1)/Gene Therapy
Gene therapies that treat arterial obstruction outside of the heart by inducing the formation of mature blood vessels.
Buyer Products:
|
|
|
|
Stroke |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that prevent or treat damage to nerve cells of the brain by preventing platelets from clumping together.
Buyer Products:
|
|
|
|
Thrombolytic Agents
Therapeutics that prevent or treat damage to nerve cells of the brain by dissolving blood clots in blood vessels.
Target Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Factor Xa Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Thrombolytic Agents
Therapeutics that treat obstructions of blood vessels by dissolving blood clots.
Target Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Rosacea |
|
|
|
Emollients
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by moisturizing and softening the skin.
Buyer Products:
|
|
|
|
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by inhibiting bacterial folic acid synthesis.
Buyer Products:
|
|
|
|
Vulgaris |
|
|
|
Antibacterial Agents |
|
|
|
Lincosamides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Macrolides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Keratolytic Agents
Therapeutics that soften, separate, and cause the shedding of skin.
Buyer Products:
|
|
|
|
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting para-aminobenzoic acid, a bacterial enzyme responsible for synthesis of folic acid.
Sulfonamide drugs are included.
Buyer Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Actinic Keratoses |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Therapeutics that treat actinic keratoses by blocking the synthesis of DNA.
Buyer Products:
|
|
|
|
Chronic Urticaria |
|
|
|
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.
Buyer Products:
|
|
|
|
Dermatitis |
|
|
|
Atopic (Eczema) |
|
|
|
Emollients
Topical therapeutics that soothe and soften the skin.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat atopic dermatoses by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Buyer Products:
|
|
|
|
Seborrheic (Dandruff) |
|
|
|
Anti-Mitotic Agents
Therapeutics that block the mitotic division of cells.
Buyer Products:
|
|
|
|
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.
Buyer Products:
|
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Buyer Products:
|
|
|
|
Diaper Rash |
|
|
|
Zinc Oxide
Therapeutics that treat diaper rash by forming a protective barrier against the skin.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroesophageal Disorders |
|
|
|
Nausea/Vomiting |
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Buyer Products:
Target Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Diarrhea |
|
|
|
Antiperistaltic Agents
Therapeutics that treat diarrhea by inhibiting the wavelike motion of the digestive tract.
Buyer Products:
|
|
|
|
Toxin Binding Agents
Therapeutics that treat antibiotic-associated diarrhea by binding to toxins release by C. difficile.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat Crohn's Disease by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Buyer Products:
|
|
|
|
Stomatognathic Disorders |
|
|
|
Aphthous (Canker Sores) |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat canker sores by blocking sodium channels which in turn block the passage of neural impulses.
Buyer Products:
|
|
|
|
Mucositis |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat mucositis by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Buyer Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
Target Products:
|
|
|
|
Hepatitis |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Target Products:
|
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Target Products:
|
|
|
|
Interferons/Nucleoside Analogs
Therapeutics that treat viral infections by preventing viral replication, stimulating the immune system to also fight the virus, and inhibits replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Diabetes |
|
|
|
Induced Complications |
|
|
|
Central Diabetes Insipidus |
|
|
|
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.
Buyer Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disease by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Insulin Dependent Diabetes Mellitus (IDDM)/Type 1 Diabetes |
|
|
|
Insulin Therapy |
|
|
|
Recombinant Human
Therapeutics that are derived from human genes.
Buyer Products:
|
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Bile Acid Binding Agents
Therapeutics that treat abnormally high blood glucose levels by binding bile acids in the intestine.
Buyer Products:
|
|
|
|
Cannabinoid Receptor Antagonists
Therapeutics that treat non-insulin dependent diabetes by blocking endogenous cannabinoid binding to neuronal CB1 receptors.
Buyer Products:
|
|
|
|
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 Receptor Agonists)
Therapeutics that treat non-insulin dependent diabetes by stimulating the Glucagon-Like Peptide (GLP) receptor. GLP regulates gastric emptying, insulin secretion, food intake, and glucagon secretion.
Buyer Products:
Target Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Buyer Products:
|
|
|
|
Insulin Therapy |
|
|
|
Recombinant Human
Therapeutics that are derived from human genes.
Buyer Products:
|
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitize organs to insulin.
Target Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat gouty arthritis by preventing cyclooxygenase activity.
Target Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Oxidases
Therapeutics that reduce excess uric acid by catalyzing enzymatic oxidation of uric acid into an inactive and soluble metabolite.
Buyer Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Antisense Agents
Therapeutics that treat high cholesterol by targeting specific messenger-RNA and thereby inhibiting the production of specific proteins.
Buyer Products:
|
|
|
|
Bile Acid Binding Agents
Therapeutics that treat hypercholesterolemia by binding bile acids in the intestine.
Buyer Products:
|
|
|
|
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive cholesterol level by inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Cholesteryl Ester Transfer Protein Inhibitors (CETP)
Therapeutics that treat high cholesterol by interrupting with the transfer of lipids between lipoproteins.
Target Products:
|
|
|
|
Lysosomal Storage Diseases |
|
|
|
Fabry Disease |
|
|
|
Enzyme Replacement Therapy
Therapeutics that treat Fabry's Disease by providing the missing enzymes that contributes to the disease symptoms.
Buyer Products:
|
|
|
|
Gaucher Disease |
|
|
|
Enzyme Replacement Therapy
Therapeutics that treat Gaucher's Disease by providing the missing enzymes that contributes to the disease symptoms.
Buyer Products:
|
|
|
|
Substrate Reduction Therapy (SRT)
Therapeutics that treat Gaucher's Disease by reducing the amount of glycosphingolipid (GSL) production to a level which can effectively be cleared by the naturally occurring Glucocerebrosidase in the cells.
Buyer Products:
|
|
|
|
Hurler Disease |
|
|
|
Enzyme Replacement Therapy
Therapeutics that treat Hurler's Disease by providing the missing enzyme that contributes to the disease symptoms.
Buyer Products:
|
|
|
|
Pompe Disease |
|
|
|
Enzyme Replacement Therapy
Therapeutics that treat Pompe Disease by replacing the deficient enzyme alfa alglucosidase.
Buyer Products:
|
|
|
|
Scheie Disease |
|
|
|
Enzyme Replacement Therapy
Therapeutics that treat Scheie's Disease by providing the missing enzyme that contributes to the disease symptoms.
Buyer Products:
|
|
|
|
Parathyroid Gland Disorders |
|
|
|
Hyperparathyroidism (HPT) |
|
|
|
Vitamin D Analogs
Therapeutics that act similar to Vitamin D.
Buyer Products:
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Pituitary Gland Disorders |
|
|
|
Severe Short Stature |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.
Target Products:
|
|
|
|
Turner`s Syndrome |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Hematology |
|
|
|
Hemophilia |
|
|
|
Hemophilia A |
|
|
|
Clotting Agents
Therapeutics that aid in blood coagulation.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
|
Anemia |
|
|
|
Recombinant Human Erythropoietins
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues by stimulating red blood cell production.
Buyer Products:
Target Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
Antisense Agents
Therapeutics that treat high cholesterol by targeting specific messenger-RNA and thereby inhibiting the production of specific proteins.
Buyer Products:
|
|
|
|
Bile Acid Binding Agents
Therapeutics that treat hypercholesterolemia by binding bile acids in the intestine.
Buyer Products:
|
|
|
|
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive cholesterol level by inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Cholesteryl Ester Transfer Protein Inhibitors (CETP)
Therapeutics that treat high cholesterol by interrupting with the transfer of lipids between lipoproteins.
Target Products:
|
|
|
|
Hyperphosphatemia |
|
|
|
Phosphate Binding Agents
Therapeutics that bind blood phosphorous.
Buyer Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Oxidases
Therapeutics that reduce excess uric acid by catalyzing enzymatic oxidation of uric acid into an inactive and soluble metabolite.
Buyer Products:
|
|
|
|
Hypocalcemia |
|
|
|
Vitamin D Analogs
Therapeutics that treat hypocalcemia by increasing serum levels of calcium, as well as helping the bone calcification process.
Target Products:
|
|
|
|
White Blood Cell (WBC) Disorders |
|
|
|
Neutropenia |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte (rhG-CSF)
Therapeutics that treat neutropenia by inducing the maturation and proliferation of white blood cells.
Target Products:
|
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) Associated Vasculitis |
|
|
|
Monoclonal Antibodies
Therapeutics that treat Wegener's Granulomatosis by interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Substance P Inhibitors
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking the action of a pain mediator.
Buyer Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
Target Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat Crohn's Disease by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Buyer Products:
|
|
|
|
Lupus Erythematosus |
|
|
|
Systemic (SLE) |
|
|
|
Immunosuppressants
Therapeutics that treat systemic lupus by inhibiting a full immune response.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat systemic lupus by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.
Target Products:
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Immunomodulators
Therapeutics that treat a neurodegenerative disease characterized by the gradual accumulation of plaques on the nerve sheaths by altering the immune mechanisms.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat multiple sclerosis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
Target Products:
|
|
|
|
Psoriasis |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin with a steroidal compound.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Fusion Inhibitors
Therapeutics that manage HIV by inhibiting the fusion of the HIV into human host cells where it can replicate.
Target Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
Target Products:
|
|
|
|
Glycopeptides
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Ketolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Digestive System |
|
|
|
Shigellosis |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat an infection of the intestines caused by Shigella by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Neurology |
|
|
|
Meningitis |
|
|
|
Antitubercular Agents
Therapeutics that treat inflammation of the lining of the brain and spinal cord by inhibiting bacterial and mycobacterial RNA synthesis.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Otitis Media |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the middle ear inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Bronchitis |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Target Products:
|
|
|
|
Tuberculosis |
|
|
|
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.
Target Products:
|
|
|
|
Formaldehyde Precursors
Therapeutics that prevent bacterial infections of the urinary tract by forming formaldehyde, a compound that denatures bacterial proteins.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial |
|
|
|
Combination |
|
|
|
Diphtheria/Tetanus (DT)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria and tetanus.
Buyer Products:
|
|
|
|
Diphtheria/Tetanus/Acellular Pertussis (DTaP)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria, tetanus, and acellular pertussis.
Buyer Products:
|
|
|
|
Diphtheria/Tetanus/Pertussis (DTP)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria, tetanus, and pertussis.
Buyer Products:
|
|
|
|
Single Target |
|
|
|
Meningitis
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause meningitis.
Buyer Products:
|
|
|
|
Tetanus
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause tetanus.
Buyer Products:
|
|
|
|
Typhoid Fever
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause typhoid fever.
Buyer Products:
|
|
|
|
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial or viral pathogen.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Triazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Onychomycosis (Nail) |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the nail by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Pneumocystis Carinii Pneumonia (PCP) |
|
|
|
Dihydrofolate Reductase Inhibitors/Dihydropteroate Synthetase Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by interfering with folic acid synthesis and growth of organism.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Quinines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by disrupting replication and transcription.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Hepadnavirus |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months with natural proteins that have antiviral activity.
Target Products:
|
|
|
|
Herpesvirus |
|
|
|
Cytomegalovirus (CMV) |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Herpes Labialis (Cold Sores) |
|
|
|
Viral Fusion Inhibitors
Therapeutics that treat cold sores by inhibiting fusion of viral material into human cell plasma membranes.
Buyer Products:
|
|
|
|
RNA Viruses |
|
|
|
Flavivirus |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Target Products:
|
|
|
|
Interferons/Nucleoside Analogs
Therapeutics that treat viral infections characterized by long term inflammation of the liver by enhancing the immune system and by inhibiting replication of viral DNA.
Target Products:
|
|
|
|
Orthomyxovirus |
|
|
|
Influenza A |
|
|
|
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the release of new viruses from infected cells.
Target Products:
|
|
|
|
Influenza B |
|
|
|
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza B virus by preventing the release of new viruses from infected cells.
Target Products:
|
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Fusion Inhibitors
Therapeutics that manage HIV by inhibiting the fusion of the HIV into human host cells where it can replicate.
Target Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Target Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial and viral pathogens.
Buyer Products:
|
|
|
|
Viral |
|
|
|
Combination |
|
|
|
Measles/Mumps/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles, mumps, and rubella.
Buyer Products:
|
|
|
|
Measles/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles and rubella.
.
Buyer Products:
|
|
|
|
Single Target |
|
|
|
Influenza (Flu)
Therapeutics that prevent or treat viral infections of the respiratory tract by producing or artificially increasing immunity to the Influenza virus.
Buyer Products:
|
|
|
|
Japanese Encephalitis
Therapeutics that prevent or treat viral infections characterized by inflammation of the brain by producing or artificially increasing immunity to the Japanese B Encephalitis virus.
Buyer Products:
|
|
|
|
Measles
Therapeutics that prevent or treat viral infections characterized by a red rash by producing or artificially increasing immunity to the measles virus.
Buyer Products:
|
|
|
|
Papillomavirus
Therapeutics that prevent or treat viral infections characterized by the proliferation of epithelial cells, leading to the formation of warts and possibly other related diseases such as cervical pre-cancers and cervical cancer.
Buyer Products:
|
|
|
|
Polio
Therapeutics that prevent or treat viral infections that attack motor neurons of the brainstem and spinal cord by producing or artificially increasing immunity to the poliovirus
Buyer Products:
|
|
|
|
Rabies
Therapeutics that prevent or treat viral infections that infect brain cells by producing or artificially increasing immunity to the rabies virus.
Buyer Products:
|
|
|
|
Rubella (German Measles)
Therapeutics that prevent or treat viral infections that begin in the lower respiratory tract and lead to a rash by producing or artificially increasing immunity to the rubella virus.
Buyer Products:
|
|
|
|
Variola (Smallpox)
Therapeutics that prevent or treat viral infections that cause a diffuse and extensive distribution of lesions by producing or artificially increasing immunity to the Variola virus.
Buyer Products:
|
|
|
|
Yellow Fever
Therapeutics that prevent or treat viral infections characterized by fever and hemorrhage by producing or artificially increasing immunity to the yellow fever virus.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Osteoporosis |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Buyer Products:
Target Products:
|
|
|
|
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts while not stimulating the endometrial lining of the uterus.
Target Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Buyer Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat ankylosing spondylitis interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.
Target Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat inflammation by preventing the accumulation of Substance P at the inflammation sites.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Target Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking the action of a pain mediator.
Buyer Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
Target Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Alzheimer`s Disease |
|
|
|
Serotonin Receptor Agonists/Nerve Growth Factor (NGF) Agonists
Therapeutics that treat Alzheimer's Disease by stimulating the serotonin receptors and the nerve growth factors.
Buyer Products:
|
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Buyer Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
Target Products:
|
|
|
|
Akinetic Pattern |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic
Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Myoclonic |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Immunomodulators
Therapeutics that treat multiple sclerosis by changing the actions of the immune system.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat multiple sclerosis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
Target Products:
|
|
|
|
Myasthenia Gravis (MG) |
|
|
|
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.
Buyer Products:
|
|
|
|
Neuropathy |
|
|
|
Serotonin Receptor Agonists/Nerve Growth Factor (NGF) Agonists
Therapeutics that treat neuropathy by stimulating the serotonin receptors and the nerve growth factors.
Buyer Products:
|
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Adjunctive Treatments |
|
|
|
Dopamine Receptor Agonists
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on neurons.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Panic Disorder |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Childhood/Adolescent Disorders |
|
|
|
Enuresis (Bedwetting) |
|
|
|
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.
Buyer Products:
|
|
|
|
Mood Disorders |
|
|
|
Depression |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that treat depression by stimulating neuronal activity in the prefontal cortex area of the brain.
Buyer Products:
|
|
|
|
Neurokinin-2 Receptor Antagonists
Therapeutics that treat depression by blocking the effects of NK-2, a neuropeptide that may modify serotonin and norepinephrine levels in the nervous system.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Sleep Disorders |
|
|
|
Insomnia |
|
|
|
Antihistamines
Therapeutics that treat insomnia by preventing the functions of histamine on tissues.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Female Genital Disorders |
|
|
|
Infertility |
|
|
|
Hormonal Treatments |
|
|
|
Ovulation Stimulating Agents
Therapeutics that treat infertility by stimulating the ovaries to release a mature egg.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Localized |
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage breast cancers by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat breast cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage breast cancers that have spread beyond their original tumor site by inhibiting the production of DNA.
Target Products:
|
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of breast cancer cells and inhibit the cancer cells' growth and induce their death.
Target Products:
|
|
|
|
Poly ADP-Ribose Polymerase (PARP) Inhibitors
Therapeutics that treat breast cancer by preventing tumor cells from repairing their own DNA, thus enhancing the effect of chemotherapy and radiation therapy to induce cell death.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Kaposi`s Sarcoma |
|
|
|
Interferons
Therapeutics that treat and manage cancers of spindle cells by providing a naturally occurring protein that stimulates the immune system.
Target Products:
|
|
|
|
Malignant Melanoma |
|
|
|
Raf Kinase Inhibitors
Therapeutics that treat skin cancer by interrupting the signaling pathways that are responsible for tumor cell proliferation.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Anal Cancer |
|
|
|
Papillomavirus Vaccines
Therapeutics that are meant to promote an immune response against the Papillomavirus that are involved in the pathogenesis of anal cancer.
Buyer Products:
|
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage colorectal cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.
Buyer Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage colorectal tumors that have spread beyond their original tumor site by inhibiting the production of DNA.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat colorectal cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Vascular Endothelial Growth Factor Receptor Inhibitors (VEGFR)
Therapeutics that treat metastatic colorrectal cancer by binding specifically to the tyrosine kinase domain of vascular endothelial growth factor receptor (VEGFR) and inhibiting the formation of blood vessels around tumor cells.
Buyer Products:
|
|
|
|
Gastric Cancer (Stomach Cancer) |
|
|
|
Localized |
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the stomach by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Pyrimidine Analogs
Therapeutics that treat and manage cancers of the stomach by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage stomach cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat gastric cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Hepatic Cancer (Liver Cancer) |
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage hepatic (liver) cancers of the pancreas by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.
Target Products:
|
|
|
|
Pancreatic Cancer |
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage pancreatic cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.
Buyer Products:
|
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the pancreas blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the pancreas by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.
Target Products:
|
|
|
|
Vascular Endothelial Growth Factor Receptor Inhibitors (VEGFR)
Therapeutics that treat metastatic pancreatic cancer by binding specifically to the tyrosine kinase domain of vascular endothelial growth factor receptor (VEGFR) and inhibiting the formation of blood vessels around tumor cells.
Buyer Products:
|
|
|
|
Endocrinology |
|
|
|
Thyroid Gland |
|
|
|
Localized |
|
|
|
Thyroid Stimulating Hormone (TSH)
Therapeutics that treat and manage primary tumors of the thyroid gland by enhancing the uptake of radioiodine which is aimed at ablating cancerous thyroid tissues.
Buyer Products:
|
|
|
|
Head/Neck Cancer |
|
|
|
Localized |
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage primary tumors of the head and neck by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Lymphoid |
|
|
|
Acute |
|
|
|
Lymphoblastic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Therapeutics that treat and acute lymphoblastic leukemia by interfering with the production of DNA.
Buyer Products:
|
|
|
|
Asparaginases
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by breaking down asparagine which is necessary for cell survival.
Buyer Products:
|
|
|
|
Chronic |
|
|
|
Hairy Cell |
|
|
|
Interferons
A recombinantly produced protein normally produced by the body to fight viral infection used to treat and manage a slowly progressing cancer of lymphoid cells characterized by numerous irregular cytoplasmic projections.
Target Products:
|
|
|
|
Lymphocytic (CLL) |
|
|
|
Antimetabolite Agents |
|
|
|
Adenosine Deaminase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by inhibiting the transformation of deoxyadenosine into deoxyinosine thereby impairing DNA synthesis as well as leaving the cancer cells unable to repair single stranded DNA breaks.
Buyer Products:
|
|
|
|
Cyclin-Dependent Kinase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by interfering with cyclin-dependent kinase which regulates cell cycle and division.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of leukemia cells and thereby induce their death.
Buyer Products:
Target Products:
|
|
|
|
Myeloid |
|
|
|
Acute |
|
|
|
Myelogenous (AML) |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Chronic |
|
|
|
Myelogenous (CML) |
|
|
|
Interferons
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by providing a naturally occurring protein that stimulates the immune system.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia and other cancer related conditions by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Buyer Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Hodgkin`s Disease |
|
|
|
Palliative Agents |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia and other cancer related conditions of lymphoma characterized by the presence of Reed-Sternberg cells by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Buyer Products:
|
|
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of lymphoma cells and thereby induce their death.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia and other cancer related conditions of lymphomas of B-cells and T-cells by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Metastatic |
|
|
|
Vascular Disrupting Agents (VDAs)
Therapeutics that treat sarcomas by disrupting existing and emerging tumor blood vessels and creating irreversible damage on tumor cells.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Brain Cancer |
|
|
|
Glioma |
|
|
|
Glioblastoma |
|
|
|
Monoclonal Antibodies
Therapeutics that treat and manage tumors of the glial cells by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
Target Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Non Small Cell Lung Cancer (NSCLC) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
EGFR-TK Inhibitors/Monoclonal Antibodies
Therapeutics that treat lung cancer by blocking the tyrosine kinase enzyme and by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the tyrosine kinase enzyme by switching off the signals from the epidermal growth factor receptors.
Target Products:
|
|
|
|
Hypoxic Cytotoxins
Therapeutics that treat lung cancer by targeting only cells with very low concentrations of oxygen.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat lung cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat non-small cell lung cancer (NSCLC) by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels to tumor cells.
Buyer Products:
|
|
|
|
Small Cell Lung Cancer (SCLC) |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Therapeutics that treat and manage cancers of the small cells in the lung by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Cervical Cancer |
|
|
|
Localized |
|
|
|
Papillomavirus Vaccines
Therapeutics that are meant to promote an immune response against the Papillomavirus that are involved in the pathogenesis of cervical cancer.
Buyer Products:
|
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that treat kidney cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Vaccines
Therapeutics that are meant to treat and manage advanced and metastatic cancers of the kidneys by eliciting a specific immune response against the cancer cells.
Buyer Products:
|
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Monoclonal Antibodies
Therapeutics that treat ovarian cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that treat and manage ovarian cancers that have spread beyond their original tumor site by binding to specific structures on the surface of the tumor, eliciting a reaction which results in tumor cell death.
Target Products:
|
|
|
|
Prostate Cancer |
|
|
|
Metastatic |
|
|
|
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.
Buyer Products:
|
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the prostate by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat prostate cancer by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels to tumor cells.
Buyer Products:
|
|
|
|
Urinary Bladder Cancer |
|
|
|
Papillocarcinoma |
|
|
|
Vaccines
Therapeutics that are meant to promote an immune response against a patient's bladder cancer.
Buyer Products:
|
|
|
|
Transitional Cell Carcinoma |
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers arising from the lining of the bladder by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Vaccines
Therapeutics that treat and mange cancers arising from the lining of the bladder by stimulating the bodies immune system to combat the cancer.
Buyer Products:
|
|
|
|
Vulvar Cancer |
|
|
|
Squamous Cell Carcinoma |
|
|
|
Papillomavirus Vaccines
Therapeutics that promote an immune response against the Papillomavirus that are involved in the pathogenesis of vaginal and vulvar cancers.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Edema |
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular edema by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.
Target Products:
|
|
|
|
Macular Degeneration (AMD) |
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular degeneration by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.
Target Products:
|
|
|
|
Retinitis |
|
|
|
AIDS-Related Cytomegalovirus (CMV) Retinitis |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Retinopathy |
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat general retinopathy by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Reversal |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Therapeutics that reverse general anesthesia by competitively inhibiting benzodiapizines at the GABA receptors, thus reducing their effect and reversing the anesthesia.
Target Products:
|
|
|
|
Local |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat pain by blocking the movement of sodium ions and thus the initiation and conduction of nerve impulses across the neuronal membrane.
Buyer Products:
|
|
|
|
Narcotics |
|
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Opioid Analgesics
Therapeutics that treat pain by providing the body with a milder opioid substitute.
Buyer Products:
|
|
|
|
Non-Narcotics |
|
|
|
Analgesics Combinations |
|
|
|
Analgesics/Antipyretics
Therapeutics that treat pain and fever by inhibiting the action of prostaglandins.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
Target Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) Combinations |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Decongestants
Therapeutic combinations that produce insensibility or numbness through the inhibition of prostoglandins while also preventing nasal decongestion.
Target Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat pain by inhibiting the accumulation of Substance P at the inflammation site.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Monoclonal Antibodies
Therapeutics that treat asthma with monoclonal antibodies.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.
Buyer Products:
|
|
|
|
Cystic Fibrosis (CF) |
|
|
|
Recombinant Human Deoxyribonuclease I
Therapeutics that relieve symptoms of cystic fibrosis by hydrolyzing the DNA in the sputum of cystic fibrosis patients thus reducing viscosity of the secretions and aiding lung function.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.
Buyer Products:
|
|
|
|
Decongestants/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up and help in ejection of mucous.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
Cardiovascular System |
|
|
|
Complications |
|
|
|
Peripheral Arterial Occlusion |
|
|
|
Thrombolytic Agents
Therapeutics that treat diseases of the blood vessels outside the heart by dissolving blood clots.
Target Products:
|
|
|
|
General |
|
|
|
Complications |
|
|
|
Nausea/Vomiting |
|
|
|
Serotonin Receptor Antagonists
Therapeutics that prevent or treat post surgical nausea and vomiting by blocking the receptors that bind serotonin, a neurotransmitter.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.
Buyer Products:
|
|
|
|
Toxicology |
|
|
|
Animal Poisoning |
|
|
|
Scorpions |
|
|
|
Immunoglobulins
Therapeutics that treat scorpion bites with target specific proteins that neutralize the poison.
Buyer Products:
|
|
|
|
Snakes |
|
|
|
Immunoglobulins
Therapeutics that treat snake bites with target specific proteins that neutralize the poison.
Buyer Products:
|
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Target Products:
|
|
|
|
Nicotine (Smoking Cessation) |
|
|
|
Cannabinoid Receptor Antagonists
Therapeutics that treat nicotine withdrawal by blocking endogenous cannabinoid binding to neuronal CB1 receptors.
Buyer Products:
|
|
|
|
Nicotinic Receptor Agonists
Therapeutics that treat nicotine withdrawal by activating nicotine receptors thus reducing cravings for nicotine.
Buyer Products:
|
|
|
|
Transplantation |
|
|
|
Bone Marrow |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Neutropenia |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte (rhG-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cells called granulocytes.
Target Products:
|
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cell colonies.
Buyer Products:
|
|
|
|
Heart |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that help manage and suppress the response of the immune system to foreign tissue.
Target Products:
|
|
|
|
Hepatic (Liver) |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Target Products:
|
|
|
|
Lung |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Rejection Prophylaxis |
|
|
|
Immunoglobulins
Therapeutics that prevent the rejection of lung transplants with target specific proteins.
Buyer Products:
|
|
|
|
Pancreas |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Peripheral Blood Progenitor Cell Transplant (PBPCT) |
|
|
|
Preparation |
|
|
|
Stem Cell Mobilizer
Therapeutics used for peripheral blood progenitor cell transplantation by blocking a specific cellular receptor, CXCR4, and triggering the movement of stem cells out of the bone marrow and into circulating blood.
Buyer Products:
|
|
|
|
Recovery |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cell colonies.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the management of rejection and infection in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Renal (Kidney) |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Rejection Prophylaxis |
|
|
|
Immunoglobulins
Therapeutics that prevent the rejection of kidney transplants with target specific proteins.
Buyer Products:
|
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Target Products:
|
|
|
|
Monoclonal Antibodies
Protein-based therapeutics that target specific substances like proteins.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the management of rejection and infection associated with transplantation in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Urinary Retention |
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat the sudden inability to pass urine by increasing blood flow and decreasing the constriction on the urinary tract.
Buyer Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Anemia |
|
|
|
Recombinant Human Erythropoietins
Therapeutics that treat the condition resulting from the scarcity of red blood cells by inducing the production of red blood cells.
Buyer Products:
Target Products:
|
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.
Buyer Products:
Target Products:
|
|
|
|
Hyperparathyroidism |
|
|
|
Vitamin D Analogs
Therapeutics that provide the body with vitamin D like substances that help regulate the levels of calcium and phosphate in the blood.
Buyer Products:
|
|
|
|
Hyperphosphatemia |
|
|
|
Phosphate Binding Agents
Therapeutics that treat abnormal levels of phosphate in the blood by binding to excess phosphate groups.
Buyer Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disease by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Weight Management |
|
|
|
Obesity |
|
|
|
Cannabinoid Receptor Antagonists
Therapeutics that suppress appetite by blocking endogenous cannabinoid binding to neuronal CB1 receptors.
Buyer Products:
|
|
|
|
Lipase Inhibitors
Therapeutics that reduce the absorption of fat by inhibiting production of lipase, which is an enzyme that helps breaking down fat in the food.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Wound Management |
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of wounds in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Healthcare Services |
|
|
|
Healthcare Distributors |
|
|
|
Pharmaceuticals Distributors |
|
|
|
Wholesale
Wholesale drug distribution involves the purchase of drugs and other health products from manufacturers specifically for re-sale and distribution to retail pharmacies, hospitals, managed care organizations, and other entities.
Buyer Products:
|
|
|
|
Patient Care |
|
|
|
Ambulatory/Outpatient |
|
|
|
Diagnostic |
|
|
|
Clinical Laboratories |
|
|
|
Pathology
Similar to routine clinical lab services, pathology services are provided by licensed medical physicians and therefore may involve the additional role of diagnosis and consultation of results with the referring physician.
Target Products:
|
|
|
|
Medical Devices |
|
|
|
Clinical Diagnostics |
|
|
|
Chemistry |
|
|
|
Analyzers |
|
|
|
Clinical Chemistry
Analyzers used to quantify various chemicals in blood plasma or serum samples. Blood gas and protein analyzers are included.
Target Products:
|
|
|
|
Urinalysis
Analyzers used to perform chemical, physical and microscopic analysis of urine.
Target Products:
|
|
|
|
Home Testing |
|
|
|
Glucose Testing/Diabetes Monitoring |
|
|
|
Invasive |
|
|
|
Continuous Analysis
Glucose test devices which measure patient glucose levels on a continual basis.
Target Products:
|
|
|
|
Random Analysis
Glucose test devices which measure patient glucose levels on a random basis.
Target Products:
|
|
|
|
Test Strips
Specific glucose test devices used with glucose monitors.
Target Products:
|
|
|
|
Point of Care Testing |
|
|
|
Critical Care Analysis |
|
|
|
Analyzers
Chemistry analyzers which may be used for the chemical analysis of body fluids and designed for use at the bedside during the course of patient care.
Target Products:
|
|
|
|
Test Cartridges
Specific analyte test devices used in conjunction with critical care chemistry analyzers.
Target Products:
|
|
|
|
Kits |
|
|
|
Cardiac
Test kits used to aid in the diagnosis of heart conditions.
Target Products:
|
|
|
|
Reagents |
|
|
|
Calibrators
Specific standards of known concentration for analytes that are used to define test performance of chemistry analyzers, including blood gas analyzers and other routine analyte analyzers.
Target Products:
|
|
|
|
Controls
Materials with known concentrations used to verify the accuracy of test systems, including blood gas system, routine system, microbiology system, and other specialized systems.
Target Products:
|
|
|
|
Test Kits |
|
|
|
Genetic/Molecular Diagnostics |
|
|
|
Disease Diagnosis |
|
|
|
Infectious Diseases |
|
|
|
Automated Analyzers
Analyzers designed for genetic probe assays to detect and quantitate microorganisms.
Target Products:
|
|
|
|
Reagents |
|
|
|
Bacterial |
|
|
|
Tuberculosis
Genetic probe for detection and/or quantitation of Mycobacterium tuberculosis.
Target Products:
|
|
|
|
Viral |
|
|
|
Cytomegalovirus
Genetic probe for detection and/or quantitation of Cytomegalovirus.
Target Products:
|
|
|
|
Hepatitis B Virus
Genetic probes for detection and/or quantitation of HBV.
Target Products:
|
|
|
|
Hepatitis C Virus
Genetic probes for detection and/or quantitation of HCV.
Target Products:
|
|
|
|
Human Immunodeficiency Virus (HIV)
Genetic probes for detection and quantification of HIV.
Target Products:
|
|
|
|
Human Papilloma Virus
Genetic probes for the detection of HPV.
Target Products:
|
|
|
|
Influenza (Flu)
Genetic probes for detection and/or quantitation of Influenza (Flu) virus.
Target Products:
|
|
|
|
West Nile Virus
Genetic probes for detection and/or quantitation of West Nile Virus.
Target Products:
|
|
|
|
Oncology |
|
|
|
Colorectal Cancer/Colon Cancer
Tests designed to diagnose colorectal cancer/colon cancer through genetic detection and analysis.
Target Products:
|
|
|
|
Hematological Cancers
Tests designed to diagnose/analyze hematological cancers such as leukemia, lymphomas and myelodysplastic syndromes through genetic detection and analysis.
Buyer Products:
|
|
|
|
Pharmacogenetic
Tests designed to determine patients' reactions to specific medications based on their genes.
Target Products:
|
|
|
|
Urinalysis
Test kits used to perform chemical and physical analysis of urine.
Target Products:
|
|
|
|
Hematology/Hemostasis |
|
|
|
Hematology |
|
|
|
Analyzers |
|
|
|
Multiple Parameter
Hematology analyzers designed for use in determining multiple hematological parameters in a clinical setting.
Target Products:
|
|
|
|
Hemostasis |
|
|
|
Analyzers |
|
|
|
Automated
Automated coagulation analyzers.
Target Products:
|
|
|
|
Reagents |
|
|
|
Test Kits |
|
|
|
Specialty Assays
Test kits used to assay for special coagulation factors, and platelet function test kits. Heparin test kits included.
Buyer Products:
|
|
|
|
Thrombin/Thromboplastin
Test kits used to perform thrombin time, prothrombin time, and activated partial thromboplastin time assays.
Target Products:
|
|
|
|
Histology |
|
|
|
Imaging Systems |
|
|
|
Cytopathology
Systems designed to enhance microscopic visualization of human cells through camera, video or digital viewing processes.
Target Products:
|
|
|
|
Processing Equipment |
|
|
|
Slide Processing
Slide processing equipment including slide labelers, slide makers, and immunohistochemistry and in-situi hybridization slide stainers.
Target Products:
|
|
|
|
Tissue Processing
Instrument used for the automated processing and embedding of tissue samples.
Target Products:
|
|
|
|
Reagents |
|
|
|
Biomolecular Stains
Vital reagents used in the staining of tissue in order to view microscopically for pathology.
Target Products:
|
|
|
|
Kits |
|
|
|
DNA Probes
Staining kits which utilize DNA probes to mark specific cells for staining.
Target Products:
|
|
|
|
In-Situ Hybridization (ISH)
Staining kits which utilize In-Situ hybridization techniques to mark specific cells for staining.
Target Products:
|
|
|
|
Preparation/Preservation
Reagents used for preservation of tissues and preparation of tissues for analysis.
Target Products:
|
|
|
|
Immunoassays |
|
|
|
Analyzers |
|
|
|
Multiple Assay
Immunoassay analyzer designed to perform multiple assays over multiple modalities.
Target Products:
|
|
|
|
Reagents |
|
|
|
Calibrators
Specific standards of known concentration for analytes that are used to define and or measure test performance of immunoassay test kits and systems.
Target Products:
|
|
|
|
Controls
Reagents used to verify the function and reliability of immunoassay test kits and systems.
Target Products:
|
|
|
|
Test Kits |
|
|
|
Cardiovascular System |
|
|
|
Cardiac
Immunoassay kits used to screen, diagnose or monitor cardiac conditions.
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial
Immunoassay kits which test for the presence of infectious diseases or previous infection caused by bacteria.
Buyer Products:
Target Products:
|
|
|
|
Viral
Immunoassay kits which test for the presence of infectious disease or previous infection caused by viruses.
Target Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer
Diagnostic assay used to detect specific breast tumor or cancer markers.
Target Products:
|
|
|
|
Digestive System Cancer
Diagnostic assay used to detect specific digestive system cancer markers.
Target Products:
|
|
|
|
Multiple Tumor
Diagnostic assay used to detect markers associated with multiple cancer types.
Target Products:
|
|
|
|
Opthalmology
Immunoassay kits used to quantify markers associated with opthalmic diseases.
Target Products:
|
|
|
|
Toxicology/Drugs Of Abuse |
|
|
|
Drugs Of Abuse
Immunoassay test kits which test for drugs of abuse in body fluids.
Target Products:
|
|
|
|
Therapeutic Drugs
Immunoassay test kits which measure levels of therapeutic drugs in body fluids.
Target Products:
|
|
|
|
Specimen Collection |
|
|
|
Blood |
|
|
|
Capillary |
|
|
|
Lancets
Sharps type of device used to puncture the skin in order to collect a capillary blood sample.
Target Products:
|
|
|
|
Drug Delivery |
|
|
|
Infusion Therapy |
|
|
|
Delivery Systems |
|
|
|
Insulin |
|
|
|
Pumps |
|
|
|
External/Random Analysis Monitoring System
External pump that delivers insulin to the patient and measure patient glucose levels as a blood sample is obtained.
Target Products:
|
|
|
|
Implanted
Implanted pump that delivers insulin to the patient.
Target Products:
|
|
|
|
Percutaneous (Subcutaneous/Intramuscular/Intravenous) |
|
|
|
Automatic Injectors
Pen-shaped medical devices used to contain and deliver liquid medications to a specified needle depth with a press of a button.
Buyer Products:
|
|
|
|
Syringes |
|
|
|
General Purpose |
|
|
|
Permanent Needle
General glass or plastic syringes with a built-in fixed needle.
Buyer Products:
|
|
|
|
Specialty |
|
|
|
Insulin
Syringes designed for the delivery of insulin for diabetic patients
Buyer Products:
|
|
|
|
Ear/Nose/Throat (ENT) |
|
|
|
Surgical |
|
|
|
Procedure/Region Specific |
|
|
|
Nose/Sinus |
|
|
|
Accessories |
|
|
|
Surgical Sealants
Glue like material used to close up surgery incisions.
Buyer Products:
|
|
|
|
General Surgery |
|
|
|
Invasive |
|
|
|
Procedure/Region Specific |
|
|
|
Hernia Repair |
|
|
|
Grafts/Mesh
Mesh or soft tissue used to repair the opening in an abnormal hernia.
Buyer Products:
|
|
|
|
Surgical-Site Treatments |
|
|
|
Anti-Adhesives/Anti-Scarring |
|
|
|
Membranes
Membrane-based products applied during interventional procedures to prevent adhesion to medical devices or to prevent scarring of the surgical sites
Buyer Products:
|
|
|
|
Orthopedics |
|
|
|
Surgical |
|
|
|
Procedure Specific |
|
|
|
Joint Replacement/Reconstruction |
|
|
|
Accessories |
|
|
|
Allografts |
|
|
|
Cartilage
Tissue obtained from cadavers to compensate for excessive tissue removal.
Buyer Products:
|
|
|
|
Treatment |
|
|
|
Braces/Supports |
|
|
|
Active
Braces that can be worn during physical activity to support ankle, elbow, arm, knee, shoulder and wrist.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
General Purpose |
|
|
|
Cold Therapy
Devices that use cold temperatures to ease pain associated with musculoskeletal injuries.
Buyer Products:
|
|
|
|
Patches
Patch like devices which deliver controlled release pain medication subcutaneously.
Buyer Products:
|
|
|
|
Joint/Region Specific |
|
|
|
Ankle/Foot |
|
|
|
Viscosupplementation
Devices used to mimic the synovial fluid in the ankle/shoulder joint in order to relieve pain.
Buyer Products:
|
|
|
|
Hip |
|
|
|
Viscosupplementation
Devices used to mimic the synovial fluid in the hip joint in order to relieve pain.
Buyer Products:
|
|
|
|
Knee |
|
|
|
Viscosupplementation
Devices used to mimic the synovial fluid in the knee joint in order to relieve pain associated with osteoarthritis.
Buyer Products:
|
|
|
|
Plastic/Reconstructive Surgery |
|
|
|
Surgical |
|
|
|
Procedure/Region Specific |
|
|
|
Implants |
|
|
|
Facial |
|
|
|
Injectable |
|
|
|
Polymer-Based
Injectable implants composed of polymers, or plastics.
Buyer Products:
|
|
|
|
Skin Grafts |
|
|
|
Artificial Skin |
|
|
|
Acellular
Skin grafts that are do not consist of living human cells.
Buyer Products:
|
|
|
|
Cellular
Skin grafts that contain living human cells.
Buyer Products:
|
|
|
|
Treatment |
|
|
|
Wrinkle Removal |
|
|
|
Hyaluronic Acid
Devices consisting of hyaluronic acid, which reduces wrinkles by hydrating and repairing skin tissue.
Buyer Products:
|
|
|
|
Radiology |
|
|
|
Nuclear |
|
|
|
Gamma Camera |
|
|
|
Contrast Agents |
|
|
|
Radionuclides |
|
|
|
Adjuncts
Radioactive materials that are introduced to the body for nuclear imaging purposes.
Buyer Products:
|
|
|
|
Nutritional Health |
|
|
|
Complementary and Alternative Medicine (CAM) |
|
|
|
Traditional Chinese Medicine (TCM)
Drugs and therapies that originate from an ancient Oriental medical system developed in China to both support general health and treat diseases. The most common types of TCM include acupuncture, food therapy and herbal medicine.
Buyer Products:
|
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
Children`s Health
Products consisting of dietary/naturopathic supplements that are intended to support infants and children's health.
Buyer Products:
|
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
|
|
|
|
Weight Management
Products consisting of dietary/naturopathic supplements that are intended to manage obesity, overweight and underweight.
Buyer Products:
|
|
|
|
Women`s Health
Products consisting of dietary/naturopathic supplements that are intended to support women's health.
Buyer Products:
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Analytical Services
The Analytical Services Subsector includes outsourced services that utilize analytical instruments to analyze biological and chemical samples.
Target Products:
|
|
|
|
Bioanalytical Services |
|
|
|
Nucleic Acid Sequencing
Bioanalytical services that identify the location of each nucleotide in a nucleic acid sample.
Target Products:
|
|
|
|
Nucleic Acid Synthesis
Bioanalytical services that produce nucleic acids from individual nucleotides.
Target Products:
|
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Medical Device OEM
Contract Manufacturing Organizations that manufacture (and/or design, develop) medical devices and products for other organizations.
Buyer Products:
|
|
|
|
Sales/Marketing
Outsourced companies that provide biopharmaceutical and medical device companies with contract sales and marketing services.
Buyer Products:
|
|
|
|
Drug Delivery Technology |
|
|
|
Oral Delivery |
|
|
|
Lipid Based
Drug Delivery Technologies used to deliver drugs in a liposomal/lipid formulation.
Buyer Products:
|
|
|
|
Drug Discovery Services |
|
|
|
Lead Discovery/Validation/Optimization |
|
|
|
Assay Development
Bioanalytical services that are used to develop biologically based tests for use in high throughput screening (HTS).
Target Products:
|
|
|
|
High Throughput Screening (HTS)
Bioanalytical services that allow for the biological testing of up to 10,000 compounds each day.
Target Products:
|
|
|
|
Lead Biologics |
|
|
|
Antibodies
Biological lead compounds which have a specific amino acid sequence that only interacts with specific substances to cause an immunological response.
Target Products:
|
|
|
|
Target Discovery/Validation |
|
|
|
Services
Drug discovery services that discover and validate drug targets for the development of novel biopharmaceutical drugs.
Target Products:
|
|
|
|
Scientific Products |
|
|
|
Analytical Instruments |
|
|
|
Automation/Processing Equipment |
|
|
|
Automation Equipment |
|
|
|
Robotic Instruments |
|
|
|
Workstations
Robotic instrument systems that transfer liquid and gas samples and also heat and cool samples.
Target Products:
|
|
|
|
Bioanalytical Instruments |
|
|
|
Bioanalytical Consumables |
|
|
|
Cell Biology |
|
|
|
Cell Culture |
|
|
|
Cell Lines
Cell biology consumables that is a permanently established cell culture which proliferates indefinitely given appropriate fresh medium and space.
Target Products:
|
|
|
|
Hybridomas
Cell culture reagents that are used to support Hybridomas for antibody production.
Target Products:
|
|
|
|
Media
Cell biology consumables used for the growth of cells or organs.
Target Products:
|
|
|
|
Reagents |
|
|
|
Lymphokines/Cytokines
Cell culture reagents that are used during cellular assays.
Target Products:
|
|
|
|
Stains/Dyes
Cell culture reagents used for the coloration of samples.
Target Products:
|
|
|
|
Immunology |
|
|
|
Kits |
|
|
|
Enzyme-Linked Immunoabsorbent Assay (ELISA)
Kits used for the generalized analysis of serum samples for the detection of antibodies to infectious diseases.
Target Products:
|
|
|
|
Reagents |
|
|
|
Proteins |
|
|
|
Antibodies
Immunology proteins that are used for the detection of specific substances, including conjugated, unconjugated, monoclonal and polyclonal antibodies.
Target Products:
|
|
|
|
Cytokines
Immunology reagents that are used as intracellular mediators.
Target Products:
|
|
|
|
Enzymes
Immunology reagents that are produced by a living organism to catalyze a chemical reaction.
Target Products:
|
|
|
|
Molecular Biology |
|
|
|
Electrochemiluminescence (ECL) |
|
|
|
Reagents
Chemicals used in the preparation and analysis of samples.
Target Products:
|
|
|
|
Nucleic Acid Analysis |
|
|
|
Automated Nucleic Acid Purification Systems
Fully automated systems for purification of DNA/RNA from blood samples.
Target Products:
|
|
|
|
Kits |
|
|
|
Nucleic Acid |
|
|
|
Sequencing
Nucleic acid analysis kits that are used for the sequencing of genetic samples.
Target Products:
|
|
|
|
Transfection
Nucleic acid analysis kits that are used for the introduction of DNA into a recipient eukaryote cell and its subsequent integration into the recipient cells chromosomal DNA
Target Products:
|
|
|
|
Polymerase Chain Reaction (PCR) |
|
|
|
Amplification
Polymerase chain reaction (PCR) consumables used for the amplification of genetic samples.
Target Products:
|
|
|
|
Detection
Polymerase chain reaction (PCR) consumables used for the detection of genetic samples.
Target Products:
|
|
|
|
Purification
Polymerase chain reaction (PCR) consumables used for the purification of genetic samples.
Target Products:
|
|
|
|
Reagents |
|
|
|
Nucleic Acids
Nucleic acid analysis reagents that are made of nucleotides.
Target Products:
|
|
|
|
Protein Analysis |
|
|
|
Kits |
|
|
|
Detection
Protein analysis kits used for the detection of amino acids.
Target Products:
|
|
|
|
Expression
Kits used to perform protein expression analysis.
Target Products:
|
|
|
|
Biomolecular |
|
|
|
Microarray Technology |
|
|
|
Consumables
Molecular biology consumables used for microarray and biochip instrumentation. Includes kits, chips, and reagents.
Target Products:
|
|
|
|
Microplate Readers |
|
|
|
Accessories
Supplementary products used to enhance the performance of a microplate reader, including detectors, incubators, dispensers, plate handlers, validation plates, and washers. Also includes consumable microplate reader kits.
Target Products:
|
|
|
|
Systems |
|
|
|
Multiple Parameter
Microplate reader systems that used a combination of fluorescent, luminescent, and/or photoemission detectors.
Target Products:
|
|
|
|
Single Parameter |
|
|
|
Electrochemiluminescence (ECL)
Microplate reader systems that use electrochemiluminescent (ECL) detectors.
Target Products:
|
|
|
|
Sequencers |
|
|
|
Automated |
|
|
|
Nucleic Acid
Automated sequencers that employ gel electrophoresis or capillary electrophoresis to analyze nucleic acid samples.
Target Products:
|
|
|
|
Synthesizers |
|
|
|
Deoxyribonucleic Acid (DNA)/Oligonucleotides
Synthesizer system used for the identification and synthesis of nucleic acid samples.
Target Products:
|
|
|
|
Peptides
Synthesizer systems used for the identification and synthesis of peptide samples.
Target Products:
|
|
|
|
Thermal Cyclers |
|
|
|
Accessories
Supplementary products used to enhance the performance of a thermal cycler.
Target Products:
|
|
|
|
Systems
Thermal cycler components assembled as a single unit.
Target Products:
|
|
|
|
Cellular |
|
|
|
Flow Cytometers |
|
|
|
Systems
Flow cytometer components assembled as a single unit.
Target Products:
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
GlaxoSmithKline plc (ADR)
|
|
n/a | 213,370.532 | 70.94 | 10.95 | 4.78 | 4.70 | n/a | |
|
Novartis AG (ADR)
|
|
n/a | 165,396.330 | 17.17 | 11.05 | 3.10 | 2.89 | 15,036.03 | |
|
Pfizer Inc.
|
|
n/a | 160,076.894 | 18.94 | 9.04 | 2.37 | 2.41 | n/a | |
|
Merck & Co., Inc.
|
|
n/a | 109,234.243 | 68.06 | 9.43 | 2.37 | 2.31 | 25.58 | |
|
Abbott Laboratories
|
|
n/a | 80,325.345 | 17.90 | 11.13 | 2.20 | 2.07 | n/a | |
|
Bayer AG (ADR)
|
|
n/a | 68,305.888 | 37.67 | 13.51 | 1.35 | 1.27 | n/a | |
|
AstraZeneca plc (ADR)
|
|
n/a | 67,862.281 | 8.43 | 6.87 | 2.04 | 2.01 | 57.32 | |
|
Amgen, Inc.
|
|
n/a | 53,933.666 | 11.76 | 11.51 | 3.56 | 3.56 | 5.05 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 46,948.790 | 14.04 | 12.54 | 2.38 | 2.29 | 6.29 | |
|
Eli Lilly & Co.
|
|
n/a | 43,215.709 | 8.86 | 8.72 | 1.84 | 1.84 | 4.69 | |
|
Celgene Corporation
|
|
n/a | 26,782.323 | 29.70 | 18.72 | 6.76 | 5.98 | 29.42 | |
|
Allergan, Inc.
|
|
n/a | 24,638.642 | n/a | 21.94 | 4.89 | 4.58 | 13.18 | |
|
Biogen Idec Inc.
|
|
n/a | 22,895.859 | 21.20 | 16.02 | 4.76 | 4.67 | 8.40 | |
|
Dr. Reddy's Laboratories Limited (ADR)
|
|
n/a | 5,821.996 | 23.85 | 15.67 | 3.53 | 2.87 | n/a | |
|
Regeneron Pharmaceuticals, Inc.
|
|
n/a | 4,909.940 | n/a | -30.17 | 10.50 | 10.49 | 9.48 | |
|
Amylin Pharmaceuticals, Inc.
|
|
n/a | 1,699.778 | n/a | -13.05 | 2.63 | 2.89 | 5.02 | |
|
Emergent BioSolutions Inc.
|
|
n/a | 776.905 | 27.97 | 19.62 | 3.01 | 2.44 | 2.61 | |
|
Genomic Health, Inc.
|
|
n/a | 745.405 | 125.61 | 183.79 | 3.99 | 3.61 | 8.12 | |
|
Targacept , Inc.
|
|
n/a | 699.224 | 41.89 | -63.56 | 6.65 | 7.06 | 6.51 | |
|
VIVUS, Inc.
|
|
n/a | 628.084 | n/a | -15.37 | n/a | 32.38 | 4.99 | |
|
AVEO Pharmaceuticals, Inc.
|
|
n/a | 609.041 | 14.87 | n/a | 3.64 | 4.02 | 3.83 | |
| Buyer | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 213,370.532 | 70.94 | 10.95 | 4.78 | 4.70 | n/a | |
|
Novartis AG (ADR)
|
|
n/a | 165,396.330 | 17.17 | 11.05 | 3.10 | 2.89 | 15,036.03 | |
| Target | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 213,370.532 | 70.94 | 10.95 | 4.78 | 4.70 | n/a | |
|
Johnson & Johnson
|
|
n/a | 181,710.369 | 14.79 | 13.37 | 2.92 | 2.79 | 7.25 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Exelixis, Inc.
|
|
41.95% | 1,195.258 | n/a | -15.03 | 6.69 | 7.87 | n/a | |
|
Beckman Coulter, Inc.
|
|
n/a | 5,934.623 | 29.34 | 18.44 | 1.61 | 1.57 | 9.37 | |
|
Open Text Corporation (USA)
|
|
n/a | 3,369.764 | 23.06 | 14.95 | 3.41 | 3.23 | n/a | |
|
ImmunoGen, Inc.
|
|
n/a | 880.415 | n/a | -13.34 | 51.12 | 50.35 | 13.58 | |
|
Medidata Solutions, Inc.
|
|
n/a | 519.289 | 21.51 | 19.21 | 3.06 | 2.87 | 11.65 | |
|
Alnylam Pharmaceuticals, Inc.
|
|
n/a | 382.946 | n/a | -6.39 | 3.97 | 5.02 | 2.64 | |
|
SciQuest, Inc.
|
|
n/a | 371.105 | 1,567.12 | 92.83 | 8.27 | 6.78 | 20.62 | |
|
Dyax Corp.
|
|
n/a | 203.343 | n/a | -5.47 | 5.14 | 4.84 | n/a | |
|
XOMA Limited
|
|
n/a | 70.265 | n/a | -2.43 | 1.67 | 1.28 | 2.90 | |
|
Andreae-Noris Zahn AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ypsomed Holding AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Gerresheimer Glas AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Buyer | |||||||||
|
Antisoma plc.
|
|
100.00% | n/a | n/a | n/a | n/a | n/a | n/a | |
|
EXACT Sciences Corporation
|
|
73.80% | 405.742 | n/a | -15.72 | 79.81 | 91.23 | 5.32 | |
| Target | |||||||||
|
Pharmasset, Inc.
|
|
100.00% | 4,034.102 | n/a | -47.34 | 4,056.60 | 628.20 | 21.00 | |
|
PDL BioPharma Inc.
|
|
86.00% | 811.539 | 7.35 | 4.97 | 2.22 | 2.16 | n/a | |
|
Seattle Genetics, Inc.
|
|
77.00% | 2,218.638 | n/a | -11.99 | 30.32 | 42.66 | 7.28 | |
|
Array BioPharma Inc.
|
|
38.60% | 121.453 | n/a | -2.31 | 1.71 | 1.69 | n/a | |
|
Marina Biotech, Inc.
|
|
34.00% | 9.342 | n/a | n/a | 3.75 | 11.63 | n/a | |
|
Tekmira Pharmaceuticals Corporation
|
|
33.30% | 27.096 | n/a | -3.35 | 1.21 | 1.08 | 3.40 | |
|
PDI, Inc.
|
|
16.30% | 93.399 | n/a | -56.82 | 0.59 | 0.49 | 2.62 | |
|
Forward Industries, Inc.
|
|
15.00% | 25.066 | n/a | n/a | 1.17 | n/a | 1.20 | |
|
SeraCare Life Sciences, Inc.
|
|
14.00% | 62.862 | 9.98 | 11.93 | 1.32 | 1.34 | 1.86 | |
|
Zueblin Immobilien Holding AG
|
|
11.40% | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Medidata Solutions, Inc.
|
|
11.00% | 519.289 | 21.51 | 19.21 | 3.06 | 2.87 | 11.65 | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Abaxis, Inc.
|
|
n/a | 619.245 | 42.60 | 38.40 | 4.31 | 3.86 | 3.77 | |
|
Government - United States
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
A&D Pharma Holdings N.V.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Buyer | |||||||||
|
Novartis AG (ADR)
|
|
n/a | 165,396.330 | 17.17 | 11.05 | 3.10 | 2.89 | 15,036.03 | |
|
Abbott Laboratories
|
|
n/a | 80,325.345 | 17.90 | 11.13 | 2.20 | 2.07 | n/a | |
| Target | |||||||||
|
Merck & Co., Inc.
|
|
n/a | 109,234.243 | 68.06 | 9.43 | 2.37 | 2.31 | 25.58 | |
|
Amgen, Inc.
|
|
n/a | 53,933.666 | 11.76 | 11.51 | 3.56 | 3.56 | 5.05 | |
|
Biogen Idec Inc.
|
|
n/a | 22,895.859 | 21.20 | 16.02 | 4.76 | 4.67 | 8.40 | |
|
Grupo Casa Saba, S.A. (ADR)
|
|
n/a | 4,512.130 | 110.39 | n/a | 1.86 | n/a | 7.40 | |
|
Qiagen NV
|
|
n/a | 4,447.091 | 31.93 | 19.96 | 4.09 | 3.83 | 10.60 | |
|
Gen-Probe Incorporated
|
|
n/a | 3,266.286 | 30.81 | 28.76 | 5.93 | 5.53 | 7.03 | |
|
InterMune, Inc.
|
|
n/a | 1,973.883 | 15.87 | -13.70 | 7.60 | 57.32 | 12.66 | |
|
Nektar Therapeutics
|
|
n/a | 872.712 | n/a | -5.70 | 6.37 | 15.02 | 4.26 | |
|
PDL BioPharma Inc.
|
|
n/a | 811.539 | 7.35 | 4.97 | 2.22 | 2.16 | n/a | |
|
Genomic Health, Inc.
|
|
n/a | 745.405 | 125.61 | 183.79 | 3.99 | 3.61 | 8.12 | |
|
Abaxis, Inc.
|
|
n/a | 619.245 | 42.60 | 38.40 | 4.31 | 3.86 | 3.77 | |
|
Micromet Inc.
|
|
n/a | 483.280 | n/a | -7.27 | 17.27 | 18.79 | 2.93 | |
|
Insmed Incorporated
|
|
n/a | 297.192 | n/a | -6.43 | 45.08 | 115.45 | 2.92 | |
|
Curis, Inc.
|
|
n/a | 245.083 | n/a | -15.65 | 68.62 | 28.35 | 7.77 | |
|
Peregrine Pharmaceuticals
|
|
n/a | 124.910 | n/a | -3.83 | 8.23 | 5.68 | 7.03 | |
|
GenMark Diagnostics, Inc
|
|
n/a | 74.272 | n/a | -2.40 | 25.88 | 10.36 | 5.01 | |
|
Trimeris, Inc.
|
|
n/a | 57.119 | 3.02 | n/a | 2.27 | n/a | 1.06 | |
|
Heska Corporation
|
|
n/a | 49.986 | 39.54 | n/a | 0.74 | n/a | 1.09 | |
|
Response Genetics, Inc.
|
|
n/a | 49.429 | n/a | -16.38 | 2.10 | 2.28 | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 213,370.532 | 70.94 | 10.95 | 4.78 | 4.70 | n/a | |
|
Novartis AG (ADR)
|
|
n/a | 165,396.330 | 17.17 | 11.05 | 3.10 | 2.89 | 15,036.03 | |
|
Merck & Co., Inc.
|
|
n/a | 109,234.243 | 68.06 | 9.43 | 2.37 | 2.31 | 25.58 | |
|
Abbott Laboratories
|
|
n/a | 80,325.345 | 17.90 | 11.13 | 2.20 | 2.07 | n/a | |
|
Bristol Myers Squibb Co.
|
|
n/a | 46,948.790 | 14.04 | 12.54 | 2.38 | 2.29 | 6.29 | |
|
Exelixis, Inc.
|
|
n/a | 1,195.258 | n/a | -15.03 | 6.69 | 7.87 | n/a | |
|
ImmunoGen, Inc.
|
|
n/a | 880.415 | n/a | -13.34 | 51.12 | 50.35 | 13.58 | |
|
Genomic Health, Inc.
|
|
n/a | 745.405 | 125.61 | 183.79 | 3.99 | 3.61 | 8.12 | |
|
Abaxis, Inc.
|
|
n/a | 619.245 | 42.60 | 38.40 | 4.31 | 3.86 | 3.77 | |
|
Micromet Inc.
|
|
n/a | 483.280 | n/a | -7.27 | 17.27 | 18.79 | 2.93 | |
|
Alnylam Pharmaceuticals, Inc.
|
|
n/a | 382.946 | n/a | -6.39 | 3.97 | 5.02 | 2.64 | |
|
Dyax Corp.
|
|
n/a | 203.343 | n/a | -5.47 | 5.14 | 4.84 | n/a | |
|
SurModics, Inc.
|
|
n/a | 202.319 | n/a | 53.36 | 3.03 | 3.13 | 1.55 | |
|
Albany Molecular Research, Inc.
|
|
n/a | 147.316 | n/a | -55.56 | 0.72 | 0.68 | 0.66 | |
|
SkyePharma PLC (ADR)
|
|
n/a | 13.956 | n/a | n/a | 0.17 | n/a | n/a | |
|
Nanogen, Inc.
|
|
n/a | 0.667 | n/a | n/a | 0.01 | n/a | n/a | |
|
Daiichi Sankyo Company, Limited
|
|
n/a | n/a | n/a | 15.77 | n/a | n/a | n/a | |
|
Eurand N.V.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
A&D Pharma Holdings N.V.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ypsomed Holding AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Buyer | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 213,370.532 | 70.94 | 10.95 | 4.78 | 4.70 | n/a | |
|
The Procter & Gamble Company
|
|
n/a | 180,568.809 | 15.81 | 16.35 | 2.24 | 2.18 | n/a | |
| Target | |||||||||
|
Hitachi, Ltd. (ADR)
|
|
n/a | 257,196.250 | 88.90 | 10.07 | 2.26 | n/a | 22.78 | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 213,370.532 | 70.94 | 10.95 | 4.78 | 4.70 | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 42,995.7 | 47,250.2 | 90,245.9 |
|
Other Revenue
|
2,338.8 | 0.0 | 2,338.8 |
| Total Revenue | 45,334.5 | 47,250.2 | 92,584.7 |
|
Cost of Revenue
|
12,666.9 | 13,233.3 | 25,900.3 |
|
SG&A Expense
|
10,894.0 | 12,399.4 | 23,293.5 |
|
Depreciation & Amortization
|
4,755.0 | 0.0 | 4,755.0 |
|
Research & Development
|
6,136.0 | 10,048.9 | 16,185.0 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
988.9 | -1,686.2 | -697.2 |
|
Unusual Expense (Income)
|
2,504.8 | -7.7 | 2,497.1 |
| Total Expenses | 37,945.7 | 33,987.9 | 71,933.6 |
|
Operating Income
|
7,388.8 | 13,262.3 | 20,651.1 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-644.4 | 0.0 | -644.4 |
|
Other, Net
|
0.0 | 524.4 | 524.4 |
| Income Before Taxes | 6,838.6 | 11,019.3 | 17,858.0 |
| Income Taxes | 1,407.4 | 2,261.0 | 3,668.4 |
| Income After Taxes | 5,431.2 | 8,758.3 | 14,189.5 |
| Minority Interest (IS) | -355.7 | -225.8 | -581.5 |
| Equity in Affiliates | 1,438.3 | 0.0 | 1,438.3 |
|
Net Income - Excl. Xord. Items
|
6,513.8 | 8,532.5 | 15,046.3 |
|
Net Income - Incl. Xord. Items
|
6,513.8 | 8,532.5 | 15,046.3 |
|
Misc. Earnings Adjustment
|
386.6 | 0.0 | 386.6 |
|
Income Avail. to Common
|
6,900.4 | 8,532.5 | 15,432.9 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
2,610.4 | 3,416.0 | 6,026.4 |
|
Basic EPS - Excl. Xord. Items
|
2.50 | 2.50 | 2.50 |
|
Basic EPS - Incl. Xord. Items
|
2.50 | 2.50 | 2.50 |
| Full Dilution Adjustment | 0.0 | -4.2 | -4.2 |
| Fully Diluted Shares Outstanding | 2,610.4 | 3,424.0 | 6,034.4 |
|
F.D. EPS - Excl. Xord. Items
|
2.50 | 2.49 | 2.49 |
|
F.D. EPS - Incl. Xord. Items
|
2.50 | 2.49 | 2.49 |
| Dividends Per Common Share | 1.75 | 1.72 | 3.47 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
0.0 | 1,923.7 | 1,923.7 |
|
ST Investments
|
n/a | 9,467.1 | 9,467.1 |
|
Accounts Receivable
|
n/a | 9,825.5 | 9,825.5 |
|
Inventory
|
n/a | 5,195.4 | 5,195.4 |
|
Other Current Assets
|
n/a | 2,441.0 | 2,441.0 |
|
Current Assets
|
n/a | 28,852.7 | 28,852.7 |
|
Accum D&A
|
n/a | 0.0 | 0.0 |
|
PPE, Net
|
n/a | 17,480.7 | 17,480.7 |
| Goodwill & Intangibles | n/a | 13,432.6 | 13,432.6 |
| Long Term Investments | n/a | 460.8 | 460.8 |
| Other Assets | n/a | 0.0 | 0.0 |
|
Other LT Assets
|
n/a | 3,535.0 | 3,535.0 |
| Total Assets | n/a | 63,761.8 | 63,761.8 |
| Liabilities | |||
| Accounts Payable | n/a | 2,160.9 | 2,160.9 |
| Payable/Accrued | n/a | 0.0 | 0.0 |
| Accrued Expenses | n/a | 6,819.2 | 6,819.2 |
|
ST Debt
|
n/a | 0.0 | 0.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
n/a | 2,299.9 | 2,299.9 |
| Other (Current) Liabilities | n/a | 4,371.0 | 4,371.0 |
|
Current Liab.
|
n/a | 15,651.0 | 15,651.0 |
|
LT Debt
|
n/a | 29,108.7 | 29,108.7 |
|
Total LT Debt
|
n/a | 29,108.7 | 29,108.7 |
| Minority Interest (BS) | n/a | 2,291.5 | 2,291.5 |
| Deferred Taxes | n/a | 924.8 | 924.8 |
|
Other LT Liab.
|
n/a | 5,891.3 | 5,891.3 |
|
Total Liabilities
|
n/a | 53,867.3 | 53,867.3 |
| Shareholders Equity | |||
| Common Stock | n/a | 0.0 | 0.0 |
| Additional Paid in Capital | n/a | 0.0 | 0.0 |
| Retained Earnings | n/a | 0.0 | 0.0 |
| Other Equity | n/a | 9,894.5 | 9,894.5 |
|
Total Equity
|
n/a | 9,894.5 | 9,894.5 |
|
Total Liab. & Equity
|
n/a | 63,761.8 | 63,761.8 |
|
Shares Outstanding
|
n/a | 3,450.3 | 3,450.3 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | n/a | 0.0 | 0.0 |
| CF Depreciation | n/a | 0.0 | 0.0 |
| CF Deferred Taxes | n/a | 0.0 | 0.0 |
| Other Non-Cash Items | n/a | -695.0 | -695.0 |
| Change in Working Capital | n/a | 15,090.8 | 15,090.8 |
| Total Cash From Operating Activities | n/a | 14,395.7 | 14,395.7 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | n/a | -3,020.6 | -3,020.6 |
| Other Investing Cash Flows | n/a | 5,921.3 | 5,921.3 |
| Total Cash From Investing Activities | n/a | 2,900.7 | 2,900.7 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | n/a | -5,003.0 | -5,003.0 |
| Purchase Or Sale of Stock | n/a | -807.7 | -807.7 |
| Purchase and Retirement of Debt | n/a | -159.4 | -159.4 |
| Other Financing Cash Flow | n/a | -3,373.1 | -3,373.1 |
| Total Cash From Financing Activities | n/a | -17,835.7 | -17,835.7 |
| Exchange Rate Effects | n/a | -44.5 | -44.5 |
| Net Change in Cash | n/a | -583.7 | -583.7 |
| Cash Taxes Paid | n/a | 2,764.8 | 2,764.8 |